Table of Contents
GARDEN GROVE, Calif.– C3 International, a biopharmaceutical company that has played a leadership role in the emerging cannabinoid therapeutics health sector, officially announced the launch of its flagship Idrasil pain management pill. Idrasil is the first standardized form of medical cannabis. It offers all of the medicinal analgesic and therapeutic benefits of cannabis, but is a superior alternative to opiates and life-threatening narcotics because physicians and caregivers can provide patients with safe, non-addictive, measurable dosages.
Conditions treated with Idrasil include, but are not limited to, AIDS; anorexia; arthritis; autism; anxiety/depression; cancer; chronic pain; glaucoma; migraines; persistent muscle spasms; Parkinson’s; seizures; severe nausea; Tourette’s Syndrome, and any other chronic or a persistent medical symptoms that substantially limit major life activities as defined in the Americans with Disabilities Act of 1990.
Idrasil also offers relief for patients struggling with clinical endocannabinoid deficiencies (CECD). CECD is a serious disorder that has a proven link to various disorders such as migraines, Fibromyalgia, Irritable Bowel Syndrome (IBS), and other treatment-resistant syndromes. Patients that want natural relief from CECD-related ailments, seek to reduce or stop existing pharmaceutical or over-the-counter dependencies, and want to curb the negative side effects or addictions of opiates and narcotics can benefit from Idrasil.
Idrasil consists of a proprietary blend of concentrated cannabis extract that is 100% natural and organic. C3’s proprietary process isolates all of the cannabinoids from the cloned cannabis plant, resulting in pure natural extraction in pill form to eliminate the unwanted euphoria and social risks associated with smoking marijuana and unpredictable dosages of edible confections. Idrasil is a natural product that looks like any pill on the market.
Additional ingredients include calcium carbonate, magnesium stearate, dicalcium phosphate, microcrystalline cellulose and silicon dioxide, which are common tabulation additives in both foods and pharmaceuticals, and are gluten free.
“Smoking and edible confections can vary greatly from plant to plant and batch to batch, which results in inconsistency and can lead to irregular analgesic or therapeutic results,” said Steele Clarke Smith, chairman and chief executive of C3 International. “With Idrasil we have introduced quality of life in a tablet that provides the same standard and consistent results dose to dose. Cannabis has been used as medicine since earliest recorded time. Our mission is to provide safe access to Idrasil, which is a patent-pending advancement in standardized natural cannabis in a pill.”
